Member Info for Jatw

I sold my holding today banking a small profit over the last 4 months.
There was a definite sell response to the results....further decline is likely.

I think the risk of falling short of the strategy is v high.
Will keep monitoring and likely to buy back but may not be for some time.

Nil....they sold their insurance business last year.

Have topped up today in anticipation of good news later this week.
Fingers crossed.

I have part sold SMS today.....
And invested in CLIN ahead of results (Thursday I think). The last trading update was positive, so may get a quick return.

UK has allowed a resumption. The US delay is most likely procedural....but you can’t rule out a US first approach influencing the return of the trial.

The dividend is rebased to 25p for FY 2020 (quarterly payments - don’t know why, two would be cheaper). Expected to increase by 10% for next 4 years. Further gains expected from reinvestment in meters and batteries.
FY trading update on 2 Feb 2021......
The dividend plan should provide a solid underpin and there is no debt to worry about for a few years.....if lockdown returns there should be less downside here.
Buy if the SP retreats in Oct-Jan.

Can’t find the date listed on HL and they don’t have a forward calendar, but it should be v soon.
Should confirm the excellent trading in 2020.
I wonder when the next product addition will be?

All sorts of puns possible from mingers to mangey best keep it clean nick name.

ESMO later this week.

In other news Gilead paid a 100% premium for immunomedics. When CKHH looks to sell completely it will be for such a premium.

Doubled profits and a huge one off gain providing liquidity for future expansion.

SP now responding...decent uplift...
Prospects also look decent....a buy for me.

The update indicator of the RNS was not working for me.....although there is one there.

Let’s see what Mr Market thinks in a few minutes....surely has to be positive.

If it were just on the financial results I would agree this should be falling....however there is a growth story and plan to get to nearly double sales by 23/24. The company is talking up its progress along this strategy.
The SP will walk along its high wire.....and will be increasingly exposed should it look like its plan is not working.
Q what is the upside if the plan does work? FOMO may result in buyingactivity.

UK productivity has been getting relatively worse for many years.....this makes it sensible to be long on overseas assets where profitable growth is easier to come by. £ getting weaker boosts returns for this strategy.

It is all about volume
Aim ave volume is about 100k shares daily.
ADS volume is 1.5m shares daily (300k ads).
The aim spread has recently narrowed but is often 5% in the morning and 2% in the afternoon with the buy close to the US implied price.....It is safer for Funds to trade in us hours

I did what I usually do when uncertain which is nothing.....I am close to break even point and can wait this down spell out....

The FY trading update indicated a lot to like....the sp responded initially but has since drifted away.

these results might start a change in momentum......especially if The accompanying trading update is positive.

The sp tells a different story though.

Interim Results due next week (Tuesday). These should be good, but the likely trading update will be more important for the market...foundations appear solid, so the sp may move up.

Well you have certainly missed out on the good run from a historic low but there should be more to come here albeit at a slower pace.
The company targets self administered treatments acquiring products consolidating manufacturing in Italy and selling internationally. Directors have form in building a business and selling. Expect a deal or two to expand the portfolio each year.....building a larger company.....as long as debt is kept under control and cash flow is positive it is a good business.
Recent gains arising from new contracts for anti septic products eg mouthwashes are likely to be sustainable with increased focus on basic health protection products.

Still a buy for me

A survivor and now looks like a winner....with additional products added and current products extending their range.
One to add regularly to the portfolio.

Announcements coming along like buses.
Another expected piece of news. It would be a shock if this were not successful given Fresco1 and the tolerability study to be reported at ESMO in a couple of weeks.
However, aPproval is about two years away given the trial duration and the regulatory approval process.